Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>)
The therapy database currently used in elasmobranchs is still mostly based on empirical data, and there are few efficacy and safety studies supporting clinical practice. In this study, meloxicam pharmacokinetics (PK) were evaluated after a single 1.5 mg/kg IM administration to a group of seven clini...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Veterinary Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2306-7381/9/5/216 |
_version_ | 1797494744040865792 |
---|---|
author | Pablo Morón-Elorza Daniela Cañizares-Cooz Carlos Rojo-Solis Teresa Álvaro-Álvarez Mónica Valls-Torres Daniel García-Párraga Teresa Encinas |
author_facet | Pablo Morón-Elorza Daniela Cañizares-Cooz Carlos Rojo-Solis Teresa Álvaro-Álvarez Mónica Valls-Torres Daniel García-Párraga Teresa Encinas |
author_sort | Pablo Morón-Elorza |
collection | DOAJ |
description | The therapy database currently used in elasmobranchs is still mostly based on empirical data, and there are few efficacy and safety studies supporting clinical practice. In this study, meloxicam pharmacokinetics (PK) were evaluated after a single 1.5 mg/kg IM administration to a group of seven clinically healthy adult undulate skates (<i>Raja undulata</i> Lacepède, 1802). Blood samples were collected before administration and at 15, 30, 60 and 90 min and 2, 4, 8, 12, 24 and 48 h after the IM injection. The meloxicam concentrations in plasma were determined using high-performance liquid chromatography, and PK parameters were calculated using a non-compartmental model approach. The mean ± SEM values of the main PK values were 1.84 ± 0.31 μg/mL for peak plasma concentration, 1.5 ± 0.24 h for time to maximum plasma concentration, 11.43 ± 2.04 h·µg/mL for area under the plasma concentration vs. time curve, 3.55 ± 0.65 h for elimination half-life, and 5.37 ± 0.94 h for mean residency time. No adverse reactions were detected. The relatively high plasma concentration and short time to maximum plasma concentration suggest that meloxicam could turn into an efficient analgesic and anti-inflammatory candidate drug to be used in skates. Further efficacy, pharmacodynamic, and multiple-dose studies with meloxicam are needed in elasmobranchs. |
first_indexed | 2024-03-10T01:38:46Z |
format | Article |
id | doaj.art-bc8ce761cee8471b8169b2a8649d8532 |
institution | Directory Open Access Journal |
issn | 2306-7381 |
language | English |
last_indexed | 2024-03-10T01:38:46Z |
publishDate | 2022-04-01 |
publisher | MDPI AG |
record_format | Article |
series | Veterinary Sciences |
spelling | doaj.art-bc8ce761cee8471b8169b2a8649d85322023-11-23T13:28:21ZengMDPI AGVeterinary Sciences2306-73812022-04-019521610.3390/vetsci9050216Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>)Pablo Morón-Elorza0Daniela Cañizares-Cooz1Carlos Rojo-Solis2Teresa Álvaro-Álvarez3Mónica Valls-Torres4Daniel García-Párraga5Teresa Encinas6Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Av. Puerta de Hierro s/n, 28040 Madrid, SpainDepartment of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Av. Puerta de Hierro s/n, 28040 Madrid, SpainVeterinary Services, Oceanogràfic, Ciudad de las Artes y las Ciencias, C/Eduardo Primo Yúfera (Científic) 1B, 46013 Valencia, SpainVeterinary Services, Oceanogràfic, Ciudad de las Artes y las Ciencias, C/Eduardo Primo Yúfera (Científic) 1B, 46013 Valencia, SpainVeterinary Services, Oceanogràfic, Ciudad de las Artes y las Ciencias, C/Eduardo Primo Yúfera (Científic) 1B, 46013 Valencia, SpainFundación Oceanogràfic de la Comunitat Valenciana, C/Eduardo Primo Yúfera (Científic) 1B, 46013 Valencia, SpainDepartment of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Av. Puerta de Hierro s/n, 28040 Madrid, SpainThe therapy database currently used in elasmobranchs is still mostly based on empirical data, and there are few efficacy and safety studies supporting clinical practice. In this study, meloxicam pharmacokinetics (PK) were evaluated after a single 1.5 mg/kg IM administration to a group of seven clinically healthy adult undulate skates (<i>Raja undulata</i> Lacepède, 1802). Blood samples were collected before administration and at 15, 30, 60 and 90 min and 2, 4, 8, 12, 24 and 48 h after the IM injection. The meloxicam concentrations in plasma were determined using high-performance liquid chromatography, and PK parameters were calculated using a non-compartmental model approach. The mean ± SEM values of the main PK values were 1.84 ± 0.31 μg/mL for peak plasma concentration, 1.5 ± 0.24 h for time to maximum plasma concentration, 11.43 ± 2.04 h·µg/mL for area under the plasma concentration vs. time curve, 3.55 ± 0.65 h for elimination half-life, and 5.37 ± 0.94 h for mean residency time. No adverse reactions were detected. The relatively high plasma concentration and short time to maximum plasma concentration suggest that meloxicam could turn into an efficient analgesic and anti-inflammatory candidate drug to be used in skates. Further efficacy, pharmacodynamic, and multiple-dose studies with meloxicam are needed in elasmobranchs.https://www.mdpi.com/2306-7381/9/5/216elasmobranchchondrichthyanpainanalgesiaNSAIDHLPC |
spellingShingle | Pablo Morón-Elorza Daniela Cañizares-Cooz Carlos Rojo-Solis Teresa Álvaro-Álvarez Mónica Valls-Torres Daniel García-Párraga Teresa Encinas Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>) Veterinary Sciences elasmobranch chondrichthyan pain analgesia NSAID HLPC |
title | Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>) |
title_full | Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>) |
title_fullStr | Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>) |
title_full_unstemmed | Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>) |
title_short | Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>) |
title_sort | pharmacokinetics of the anti inflammatory drug meloxicam after single 1 5 mg kg intramuscular administration to undulate skates i raja undulata i |
topic | elasmobranch chondrichthyan pain analgesia NSAID HLPC |
url | https://www.mdpi.com/2306-7381/9/5/216 |
work_keys_str_mv | AT pablomoronelorza pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai AT danielacanizarescooz pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai AT carlosrojosolis pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai AT teresaalvaroalvarez pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai AT monicavallstorres pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai AT danielgarciaparraga pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai AT teresaencinas pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai |